SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells

International Journal of Molecular Medicine

Volumn 33, Issue 5, 2014, Pages 1364-1370

  Piao, Longzhen ^a,b   Park, Jisoo ^a   Li, Yuwen ^a,c   Shin, Sanghee ^a   Shin, Soyeon ^a   Kong, Gyeyeong ^a   Shrestha, Robin ^a   Tran, Quangdon ^a   Hur, Gang Min ^a   Kim, Jeong Lan ^a   Park, Jongsun ^a  

^a Chungnam National University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antipsychotic drug; Insulin; Leptin; Protein kinase b; Risperidone; Suppressor of cytokine signaling

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; INSULIN; LEPTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RISPERIDONE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 6; UNCLASSIFIED DRUG; SOCS3 PROTEIN, HUMAN; SOCS6 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; WEIGHT GAIN; DRUG EFFECTS; METABOLISM; NEUROBLASTOMA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; HUMANS; INSULIN; LEPTIN; NEUROBLASTOMA; PHOSPHORYLATION; RISPERIDONE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84899576942     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1693     Document Type: Article

References (46)

1. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL and Muller DJ: Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17: 242-266, 2012.
2. Citrome L, Jaffe A, Levine J and Lindenmayer JP: Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 66: 1512-1516, 2005.
3. Melkersson KI, Dahl ML and Hulting AL: Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 175: 1-6, 2004.
4. Scheen AJ and De Hert MA: Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 33: 169-175, 2007.
5. Grace AA: Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 31: 330-341, 2000.
6. Narendran R, Slifstein M, Guillin O, et al: Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60: 485-495, 2006.
7. Masi G, Cosenza A, Mucci M and Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40: 1206-1214, 2001.
8. Nasrallah H: A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28 (Suppl 1): 83-96, 2003.
9. Claus A, Bollen J, De Cuyper H, et al: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 85: 295-305, 1992.
10. Owens DG: Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 55: 29-35, 1994.
11. Morton GJ: Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 583: 437-443, 2007.
12. Niswender KD, Baskin DG and Schwartz MW: Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab 15: 362-369, 2004.
13. Hemmings BA and Restuccia DF: PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 4: a011189, 2012.
14. Coppari R and Bjorbaek C: Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 11: 692-708, 2012.
15. Obici S, Feng Z, Morgan K, Stein D, Karkanias G and Rossetti L: Central administration of oleic acid inhibits glucose production and food intake. Diabetes 51: 271-275, 2002.
16. Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS and Myers MG Jr: Regulation of Jak kinases by intracellular leptin receptor sequences. J Biol Chem 277: 41547-41555, 2002.
17. Myers MG Jr: Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 59: 287-304, 2004.
18. White DW, Kuropatwinski KK, Devos R, Baumann H and Tartaglia LA: Leptin receptor (OB-R) signaling. Cytoplasmic domain mutational analysis and evidence for receptor homooligomerization. J Biol Chem 272: 4065-4071, 1997.
19. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA and Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921, 1997.
20. Yoshimura A, Nishinakamura H, Matsumura Y and Hanada T: Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 7: 100-110, 2005.
21. Miyamoto S, Duncan GE, Marx CE and Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10: 79-104, 2005.
22. Friedman JM and Halaas JL: Leptin and the regulation of body weight in mammals. Nature 395: 763-770, 1998.
23. Spiegelman BM and Flier JS: Obesity and the regulation of energy balance. Cell 104: 531-543, 2001.
24. Nilsson CL and Eriksson E: Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors? J Neural Transm Gen Sect 92: 213-220, 1993.
25. Insel PA and Ostrom RS: Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol 23: 305-314, 2003.
26. Sands WA, Woolson HD, Milne GR, Rutherford C and Palmer TM: Exchange protein activated by cyclic AMP (Epac)- mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells. Mol Cell Biol 26: 6333-6346, 2006.
27. Banks AS, Li J, McKeag L, et al: Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 115: 2462-2471, 2005.
28. Mooney RA, Senn J, Cameron S, et al: Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276: 25889-25893, 2001.
29. Senn JJ, Klover PJ, Nowak IA, et al: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278: 13740-13746, 2003.
30. Ueki K, Kondo T and Kahn CR: Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434-5446, 2004.
31. Wojtal KA, Hoekstra D and van Ijzendoorn SC: cAMP-dependent protein kinase A and the dynamics of epithelial cell surface domains: moving membranes to keep in shape. Bioessays 30: 146-155, 2008.
32. Stork PJ and Schmitt JM: Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258-266, 2002.
33. Metzger BE, Buchanan TA, Coustan DR, et al: Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30 (Suppl 2): S251-S260, 2007.
34. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223, 2005.
35. Tran PV, Hamilton SH, Kuntz AJ, et al: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407-418, 1997.
36. Csernansky JG, Miller JP, McKeel D and Morris JC: Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 16: 144-149, 2002.
37. Akam E and Strange PG: Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol 67: 2039-2045, 2004.
38. Seeman P, Schwarz J, Chen JF, et al: Psychosis pathways converge via D2high dopamine receptors. Synapse 60: 319-346, 2006.
39. Albert PR, Neve KA, Bunzow JR and Civelli O: Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion. J Biol Chem 265: 2098-2104, 1990.
40. Yang BH, Son H, Kim SH, Nam JH, Choi JH and Lee JS: Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin Neurosci 58: 262-267, 2004.
41. Howard JK and Flier JS: Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 17: 365-371, 2006.
42. Bjorbak C, Lavery HJ, Bates SH, et al: SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 275: 40649-40657, 2000.
43. Rui L, Yuan M, Frantz D, Shoelson S and White MF: SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277: 42394-42398, 2002.
44. Laroche-Joubert N, Marsy S, Michelet S, Imbert-Teboul M and Doucet A: Protein kinase A-independent activation of ERK and H, K-ATPase by cAMP in native kidney cells: role of Epac I. J Biol Chem 277: 18598-18604, 2002.
45. Yee WM and Worley PF: Rheb interacts with Raf-1 kinase and may function to integrate growth factor- and protein kinase A-dependent signals. Mol Cell Biol 17: 921-933, 1997.
46. Richards JS: New signaling pathways for hormones and cyclic adenosine 3′,5′-monophosphate action in endocrine cells. Mol Endocrinol 15: 209-218, 2001.